These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
23. Regulatory T-cell therapy for autoimmune and autoinflammatory diseases: The next frontier. Esensten JH; Muller YD; Bluestone JA; Tang Q J Allergy Clin Immunol; 2018 Dec; 142(6):1710-1718. PubMed ID: 30367909 [TBL] [Abstract][Full Text] [Related]
24. Two decades of research on autoimmune liver disease in Turkey. Demir N; Ekin N; Torgutalp M; Wahlin S; Efe C Turk J Gastroenterol; 2020 Dec; 31(12):877-882. PubMed ID: 33626000 [TBL] [Abstract][Full Text] [Related]
25. Successful immunotherapy of autoimmune cholangitis by adoptive transfer of forkhead box protein 3(+) regulatory T cells. Tanaka H; Zhang W; Yang GX; Ando Y; Tomiyama T; Tsuneyama K; Leung P; Coppel RL; Ansari AA; Lian ZX; Ridgway WM; Joh T; Gershwin ME Clin Exp Immunol; 2014 Nov; 178(2):253-61. PubMed ID: 25041369 [TBL] [Abstract][Full Text] [Related]
27. Low-dose IL-2 therapy in autoimmune diseases: An update review. Zhang R; Zhao Y; Chen X; Zhuang Z; Li X; Shen E Int Rev Immunol; 2024 May; 43(3):113-137. PubMed ID: 37882232 [TBL] [Abstract][Full Text] [Related]
28. Clinical Potential of Regulatory T Cell Therapy in Liver Diseases: An Overview and Current Perspectives. Jeffery HC; Braitch MK; Brown S; Oo YH Front Immunol; 2016; 7():334. PubMed ID: 27656181 [TBL] [Abstract][Full Text] [Related]
29. Regulatory T-Cell Therapy in Liver Transplantation and Chronic Liver Disease. Hann A; Oo YH; Perera MTPR Front Immunol; 2021; 12():719954. PubMed ID: 34721383 [TBL] [Abstract][Full Text] [Related]
30. Support of precision medicine through risk-stratification in autoimmune liver diseases - histology, scoring systems, and non-invasive markers. Bossen L; Gerussi A; Lygoura V; Mells GF; Carbone M; Invernizzi P Autoimmun Rev; 2018 Sep; 17(9):854-865. PubMed ID: 30005861 [TBL] [Abstract][Full Text] [Related]
32. Expression of IL-37 Correlates With Immune Cell Infiltrate and Fibrosis in Pediatric Autoimmune Liver Diseases. Griessmair L; Pirringer L; Mountford S; Sendelhofert A; Makeschin MC; Koletzko S; Mayr D; Bufler P J Pediatr Gastroenterol Nutr; 2022 Jun; 74(6):742-749. PubMed ID: 35258491 [TBL] [Abstract][Full Text] [Related]
33. Clinical aspects and prognosis of patients with inflammatory bowel disease associated with autoimmune liver diseases. Rocha HC; Vilela EG Gastroenterol Hepatol; 2022 Feb; 45(2):83-90. PubMed ID: 34023469 [TBL] [Abstract][Full Text] [Related]
34. MicroRNAs in autoimmune liver diseases: from diagnosis to potential therapeutic targets. Huang C; Xing X; Xiang X; Fan X; Men R; Ye T; Yang L Biomed Pharmacother; 2020 Oct; 130():110558. PubMed ID: 32781357 [TBL] [Abstract][Full Text] [Related]
35. Regulatory CAR-T cells in autoimmune diseases: Progress and current challenges. Riet T; Chmielewski M Front Immunol; 2022; 13():934343. PubMed ID: 36032080 [TBL] [Abstract][Full Text] [Related]
36. Causal effect of autoimmune liver diseases on cancer: Meta-analyses of cohort studies and Mendelian randomization study. Gu D; Zhang M; Wang Y; Bai Y; Wang X; Deng G Liver Int; 2022 Oct; 42(10):2216-2226. PubMed ID: 35775855 [TBL] [Abstract][Full Text] [Related]
37. Regulatory T-cell conditioning endows activated effector T cells with suppressor function in autoimmune hepatitis/autoimmune sclerosing cholangitis. Liberal R; Grant CR; Yuksel M; Graham J; Kalbasi A; Ma Y; Heneghan MA; Mieli-Vergani G; Vergani D; Longhi MS Hepatology; 2017 Nov; 66(5):1570-1584. PubMed ID: 28597951 [TBL] [Abstract][Full Text] [Related]
39. [The immune-modulation therapy of autoimmune liver diseases]. Lian M; Ma X Zhonghua Gan Zang Bing Za Zhi; 2021 Jul; 29(7):622-624. PubMed ID: 34371531 [TBL] [Abstract][Full Text] [Related]
40. [Research advances in autoimmune liver diseases in 2016]. Li B; Wang QX; Ma X Zhonghua Gan Zang Bing Za Zhi; 2017 Feb; 25(2):100-104. PubMed ID: 28297794 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]